World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
69
Citations
26278
World Ranking
2469
National Ranking
1180

Zhiya Yu publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Zhiya Yu sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 125 publications — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Zhiya Yu D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Zhiya Yu sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 69 D-Index — 50th percentile

50% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Zhiya Yu is affiliated with the National Institutes of Health in the United States and has a substantial body of research primarily in medicine, immunology, and biochemistry, genetics, and molecular biology. Their work focuses significantly on oncology and immunology, with an emphasis on molecular biology, genetics, and related imaging techniques.

The main research topics covered by Yu include:

  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • Virus-based gene therapy research
  • T-cell and B-cell Immunology
  • CRISPR and Genetic Engineering

Yu has published extensively, contributing to multiple journals and conference abstracts. Among the notable venues where their work appears are Regular and Young Investigator Award Abstracts, Journal for ImmunoTherapy of Cancer, Science, Clinical Cancer Research, and the bioRxiv repository associated with Cold Spring Harbor Laboratory.

Frequent collaborators highlight a network of researchers who have coauthored multiple publications with Yu, including Frank J. Lowery, Steven A. Rosenberg, Sri Krishna, Nicholas P. Restifo, and Maria R. Parkhurst.

Some recent influential publications by Yu include:

  • "Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer," published in Science in 2020
  • "Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers," published in Science in 2022
  • "An engineered IL-2 partial agonist promotes CD8+ T cell stemness," published in Nature in 2021
  • "Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors," published in Cancer Immunology Research in 2022
  • "Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies," published in Cancer Cell in 2020

Yu's work spans critical issues in adoptive cell immunotherapy, neoantigen-reactive T cells, and engineered cytokine agonists that influence T cell stemness, as well as applying CRISPR-Cas9 technologies in identifying therapeutic targets.

Best Publications

  • A human memory T cell subset with stem cell-like properties

    Luca Gattinoni;Enrico Lugli;Yun Ji;Zoltan Pos

  • Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

    Luca Gattinoni;Steven E. Finkelstein;Christopher A. Klebanoff;Christopher A. Klebanoff;Paul A. Antony

  • Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

    Luca Gattinoni;Christopher A. Klebanoff;Christopher A. Klebanoff;Douglas C. Palmer;Claudia Wrzesinski

  • Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells

    Willem W. Overwijk;Marc R. Theoret;Steven E. Finkelstein;Deborah R. Surman

  • Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

    Luca Gattinoni;Xiao-Song Zhong;Douglas C Palmer;Yun Ji

  • Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function

    Madhusudhanan Sukumar;Jie Liu;Yun Ji;Murugan Subramanian

  • Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

    Rajeev K. Shrimali;Zhiya Yu;Marc R. Theoret;Dhanalakshmi Chinnasamy

  • Ionic immune suppression within the tumour microenvironment limits T cell effector function

    Robert Eil;Suman K. Vodnala;David Clever;Christopher A. Klebanoff;Christopher A. Klebanoff

  • Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8 + T cells via TLR4 signaling

    Chrystal M. Paulos;Claudia Wrzesinski;Andrew Kaiser;Christian S. Hinrichs

  • Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers

    Unknown

  • T cell stemness and dysfunction in tumors are triggered by a common mechanism.

    Suman Kumar Vodnala;Robert Eil;Rigel J. Kishton;Madhusudhanan Sukumar

  • Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature

    Pawel Muranski;Zachary A. Borman;Sid P. Kerkar;Christopher A. Klebanoff

  • Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity

    Christian S. Hinrichs;Zachary A. Borman;Lydie Cassard;Luca Gattinoni

  • Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer

    Sri Krishna;Frank J. Lowery;Amy R. Copeland;Erol Bahadiroglu

  • Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia

    Eric Tran;Dhanalakshmi Chinnasamy;Zhiya Yu;Richard A. Morgan

  • BACH2 represses effector programs to stabilize T reg -mediated immune homeostasis

    Rahul Roychoudhuri;Kiyoshi Hirahara;Kiyoshi Hirahara;Kambiz Mousavi;David Clever

  • Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.

    James N. Kochenderfer;Zhiya Yu;Dorina Frasheri;Nicholas P. Restifo

  • IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors

    Sid P. Kerkar;Romina S. Goldszmid;Pawel Muranski;Dhanalakshmi Chinnasamy

  • Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy

    Madhusudhanan Sukumar;Jie Liu;Gautam U. Mehta;Shashank J. Patel

  • Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics

    Joseph G. Crompton;Joseph G. Crompton;Joseph G. Crompton;Madhusudhanan Sukumar;Rahul Roychoudhuri;David Clever;David Clever

  • Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy

    Christian S. Hinrichs;Zachary A. Borman;Luca Gattinoni;Zhiya Yu

  • Therapeutic cancer vaccines: are we there yet?

    Christopher A. Klebanoff;Nicholas Acquavella;Zhiya Yu;Nicholas P. Restifo

Frequent Co-Authors

Nicholas P. Restifo
Nicholas P. Restifo National Institutes of Health
Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Luca Gattinoni
Luca Gattinoni University of Regensburg
Douglas C. Palmer
Douglas C. Palmer National Institutes of Health
Christopher A. Klebanoff
Christopher A. Klebanoff Memorial Sloan Kettering Cancer Center
Richard A. Morgan
Richard A. Morgan University of California, Los Angeles
Chrystal M. Paulos
Chrystal M. Paulos Emory University
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Paul F. Robbins
Paul F. Robbins National Cancer Institute
Maria R. Parkhurst
Maria R. Parkhurst National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related degrees like becoming a Psychiatric Mental Health Nurse Practitioner (PMHNP) can be a valuable option. Many students research the easiest nurse practitioner program to find flexible and accessible online options that balance rigorous coursework with manageable workload.

Choosing the right online program is essential, especially when practical experience through clinical placements is a priority. Programs with strong support for hands-on training, such as those listed under online pmhnp programs with clinical placement, help ensure graduates are well-prepared for real-world challenges.

Cost is also a major deciding factor. Students often look for cheapest online pmhnp certificate programs that offer quality education without excessive financial burden, making advanced studies accessible to a broader range of learners.

Career prospects are promising, with professionals in this field typically earning competitive salaries. To understand earning potential based on location, exploring data like how much does a dnp make provides crucial insights to guide career planning and decision-making.

Best Scientists Citing Zhiya Yu

Trending Scientists

Recently Published Articles